NASDAQ: RAPP
Rapport Therapeutics Inc Stock Ownership - Who owns Rapport Therapeutics?

Insider buying vs selling

Have Rapport Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
David BredtChief Scientific Officer2026-02-196,000$1.80
$10.80kBuy
Abraham CeesayChief Executive Officer2026-02-183,552$29.05
$103.19kSell
Abraham CeesayChief Executive Officer2026-02-182,100$29.80
$62.57kSell
Abraham CeesayChief Executive Officer2026-02-182,983$29.04
$86.64kSell
Abraham CeesayChief Executive Officer2026-02-182,281$29.80
$67.97kSell
David BredtChief Scientific Officer2026-02-17900$28.02
$25.22kSell
David BredtChief Scientific Officer2026-02-172,200$29.59
$65.11kSell
David BredtChief Scientific Officer2026-02-175,400$28.95
$156.33kSell
Abraham CeesayChief Executive Officer2026-01-205,833$26.12
$152.33kSell
Abraham CeesayChief Executive Officer2026-01-205,083$26.11
$132.74kSell

1 of 6

RAPP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RAPP insiders and whales buy or sell their stock.

RAPP Shareholders

What type of owners hold Rapport Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Third Rock Ventures V LP17.00%8,104,451$240.30MInsider
Trv GP V LLC14.97%7,135,233$211.56MInstitution
Fmr LLC14.92%7,111,865$210.87MInstitution
Arch Venture Partners XII LLC7.82%3,728,738$110.56MInsider
Arch Venture Management LLC7.82%3,728,738$110.56MInstitution
Capital International Investors7.14%3,402,529$100.88MInstitution
Cormorant Asset Management LP6.35%3,027,521$89.77MInstitution
Goldman Sachs Group Inc6.30%3,001,879$89.01MInstitution
Blackrock Inc5.10%2,431,862$72.10MInstitution
James Healy4.19%1,995,594$59.17MInsider

1 of 3

RAPP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RAPP76.03%23.97%Net SellingNet Selling
NKTR41.27%58.73%Net SellingNet Selling
OLMA78.20%21.80%Net SellingNet Selling
BHVN78.76%15.74%Net BuyingNet Selling
ORIC84.82%15.18%Net SellingNet Selling

Rapport Therapeutics Stock Ownership FAQ

Who owns Rapport Therapeutics?

Rapport Therapeutics (NASDAQ: RAPP) is owned by 107.18% institutional shareholders, 33.79% Rapport Therapeutics insiders, and 0.00% retail investors. Third Rock Ventures V LP is the largest individual Rapport Therapeutics shareholder, owning 8.10M shares representing 17.00% of the company. Third Rock Ventures V LP's Rapport Therapeutics shares are currently valued at $245.08M.

If you're new to stock investing, here's how to buy Rapport Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.